TRAW stock is turning heads today, with shares soaring to $3.41 in premarket trading = a massive 70.5% jump from yesterday’s $2.00 close. The buzz? It’s all about their promising bird flu treatment, tivoxavir marboxil.
On March 3, 2025, Traws announced breakthrough results from a study using ferrets, a common model for human flu research. Just one oral dose of tivoxavir dramatically slowed the progression of H5N1 infection, suggesting real potential for human use. Then on May 27, the FDA weighed in with support, even suggesting the “Animal Rule” pathway – which allows for quicker approvals when human trials aren’t feasible. Traws is also in talks with BARDA to potentially stockpile the medicine, opening the door for future government contracts.
Financially, the company’s in a strong spot. Their Q1 2025 earnings report, released May 15, showed $21.5 million in net income, largely thanks to a favorable warrant liability shift from a late 2024 financing deal. With $15.9 million in cash, they are financially set through the first quarter of 2026 (Q1 2025 Results). At ICAR 2025, they also presented positive data from non-human primate studies, further boosting confidence in tivoxavir’s efficacy.
